Cargando…

Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice

Detalles Bibliográficos
Autores principales:	Tian, Siyu, Ji, Kai, Wang, Meng, Wang, Fengze, Wang, Hao, Huang, Weijin, Huang, Qingrui, Yan, Jinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495183/ https://www.ncbi.nlm.nih.gov/pubmed/34620836 http://dx.doi.org/10.1038/s41421-021-00331-9

Ejemplares similares

A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD
por: Liu, Shuo, et al.
Publicado: (2022)

A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants
por: Duan, Xiaomin, et al.
Publicado: (2022)

A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
por: Huang, Qingrui, et al.
Publicado: (2021)

Publisher Correction: A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
por: Huang, Qingrui, et al.
Publicado: (2021)

Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
por: Wang, Wenjun, et al.
Publicado: (2021)

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
por: Cao, Yunlong, et al.
Publicado: (2021)

Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2
por: Lin, Yifan, et al.
Publicado: (2022)

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
por: Sun, Shihui, et al.
Publicado: (2021)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
por: Chen, Yuxin, et al.
Publicado: (2021)

SARS-CoV-2 virus: Vaccines in development
por: Huang, Qingrui, et al.
Publicado: (2021)

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

SARS-CoV-2 RBD dimers elicit response comparable to VLPs in mice
por: Love, J., et al.
Publicado: (2023)

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
por: Li, Yang, et al.
Publicado: (2020)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants
por: Liu, Junli, et al.
Publicado: (2021)

Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice
por: Ke, Qian, et al.
Publicado: (2022)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
por: Huang, Qingrui, et al.
Publicado: (2022)

A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core
por: Shi, Rui, et al.
Publicado: (2022)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
por: Liang, Qingtai, et al.
Publicado: (2022)

Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
por: Li, Qianqian, et al.
Publicado: (2022)

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
por: Wang, Shixia, et al.
Publicado: (2022)

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2
por: Li, Letian, et al.
Publicado: (2021)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Aggregation of high‐frequency RBD mutations of SARS‐CoV‐2 with three VOCs did not cause significant antigenic drift
por: Li, Tao, et al.
Publicado: (2022)

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains
por: Zhang, Ye, et al.
Publicado: (2022)

Characterizing the dynamics of BCR repertoire from repeated influenza vaccination
por: Mai, Guoqin, et al.
Publicado: (2023)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

Advances in antibody discovery from human BCR repertoires
por: Xu, Zichang, et al.
Publicado: (2022)

Dosing interval regimen shapes potency and breadth of antibody repertoire after vaccination of SARS-CoV-2 RBD protein subunit vaccine
por: Guo, Shuxin, et al.
Publicado: (2023)

3-dose of RBD vaccine is sufficient to elicit a long-lasting memory response against SARS-CoV-2 infection
por: Cong, Mengqing, et al.
Publicado: (2022)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
por: Zang, Jinkai, et al.
Publicado: (2021)

Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage
por: Traut, Caroline C, et al.
Publicado: (2023)

Structures of synthetic nanobody–SARS-CoV-2–RBD complexes reveal distinct sites of interaction and recognition of variants
por: Ahmad, Javeed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pme5tfpl30414r3bk0ief7es0g